Opinion
Video
Post Hoc Analysis of ARANOTE; Ultra-Low PSA Responses
Author(s):
Research highlights the significant benefits of achieving ultra-low PSA levels in metastatic hormone-sensitive prostate cancer, delaying disease progression effectively.
Video Player is loading.
Rationale for Ultra-Low PSA Threshold Analysis
Key Themes:
- Post hoc analysis focusing on PSA response thresholds
- Particular focus on ultra-low PSA threshold (<0.02 ng/mL)
- PSA as a surrogate biomarker in advanced prostate cancer
Expert Insights:
- Dr Shore explained the rationale for examining the ultra-low PSA threshold of <0.02 ng/mL in the ARANOTE trial.
The discussion highlighted the historical relevance of low PSA levels in predicting treatment outcomes and the potential increased sensitivity of this threshold.
Related Videos
Adam Weiner, MD, on therapeutic decision-making in metastatic prostate cancer
Real-World Safety of Androgen Receptor Inhibitors in Nonmetastatic Castration-Resistant Prostate Cancer
Fred Saad, MD, FRCP, reacts to FDA approval of darolutamide in mCSPC
The Role of Bone-Targeted Therapies
Topline Results From Recent NMIBC Trials
Exploring Nadofaragene Firadenovec: Ongoing Trials and Study Designs
First-Line mHSPC Therapy: AR Inhibitors vs Chemotherapy
Using Ultrasensitive PSA Assays in Routine Practice
Ultra-Low PSA Response as a Trial End Point or Clinical Decision Point
Outcomes in Black patients receiving darolutamide plus ADT for mHSPC
Related Content
